Cooper Companies Inc (NYSE:COO) Expected to Post Earnings of $3.27 Per Share
Brokerages predict that Cooper Companies Inc (NYSE:COO) will announce earnings per share of $3.27 for the current quarter, according to Zacks Investment Research. Nine analysts have made estimates for Cooper Companies’ earnings, with the highest EPS estimate coming in at $3.30 and the lowest estimate coming in at $3.22. Cooper Companies posted earnings per share of $2.87 during the same quarter last year, which suggests a positive year over year growth rate of 13.9%. The business is scheduled to report its next earnings results after the market closes on Thursday, December 5th.
According to Zacks, analysts expect that Cooper Companies will report full-year earnings of $12.32 per share for the current fiscal year, with EPS estimates ranging from $12.30 to $12.35. For the next year, analysts forecast that the business will report earnings of $13.10 per share, with EPS estimates ranging from $12.88 to $13.32. Zacks’ EPS averages are a mean average based on a survey of research analysts that follow Cooper Companies.
Cooper Companies (NYSE:COO) last announced its quarterly earnings results on Thursday, August 29th. The medical device company reported $3.23 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $3.16 by $0.07. The company had revenue of $679.40 million during the quarter, compared to analyst estimates of $687.60 million. Cooper Companies had a return on equity of 17.15% and a net margin of 17.08%. The firm’s revenue was up 2.9% on a year-over-year basis. During the same period in the prior year, the firm posted $3.00 earnings per share.
In other news, Director Allan E. Rubenstein sold 1,335 shares of the stock in a transaction dated Wednesday, September 11th. The stock was sold at an average price of $299.61, for a total value of $399,979.35. Following the completion of the sale, the director now owns 3,591 shares in the company, valued at $1,075,899.51. The transaction was disclosed in a legal filing with the SEC, which is available through this link. 1.70% of the stock is currently owned by company insiders.
A number of hedge funds and other institutional investors have recently modified their holdings of the business. Flagship Harbor Advisors LLC grew its stake in Cooper Companies by 62.5% during the 2nd quarter. Flagship Harbor Advisors LLC now owns 78 shares of the medical device company’s stock valued at $26,000 after purchasing an additional 30 shares in the last quarter. Signaturefd LLC grew its stake in Cooper Companies by 3.8% during the 2nd quarter. Signaturefd LLC now owns 875 shares of the medical device company’s stock valued at $295,000 after purchasing an additional 32 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank grew its stake in Cooper Companies by 0.4% during the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 10,282 shares of the medical device company’s stock valued at $3,464,000 after purchasing an additional 38 shares in the last quarter. Advisory Services Network LLC lifted its holdings in Cooper Companies by 13.6% during the 2nd quarter. Advisory Services Network LLC now owns 318 shares of the medical device company’s stock worth $107,000 after buying an additional 38 shares during the last quarter. Finally, United Capital Financial Advisers LLC lifted its holdings in Cooper Companies by 2.8% during the 2nd quarter. United Capital Financial Advisers LLC now owns 1,435 shares of the medical device company’s stock worth $483,000 after buying an additional 39 shares during the last quarter. Hedge funds and other institutional investors own 95.35% of the company’s stock.
NYSE:COO traded down $1.31 on Monday, hitting $311.78. 317,900 shares of the stock were exchanged, compared to its average volume of 319,353. The stock has a market cap of $15.52 billion, a PE ratio of 27.11, a PEG ratio of 2.31 and a beta of 0.91. The company has a current ratio of 1.29, a quick ratio of 0.73 and a debt-to-equity ratio of 0.39. The stock has a fifty day moving average of $296.89 and a 200-day moving average of $311.70. Cooper Companies has a fifty-two week low of $228.65 and a fifty-two week high of $344.32.
Cooper Companies Company Profile
The Cooper Companies, Inc operates as a medical device company worldwide. It operates through CooperVision and CooperSurgical business units. The company develops, manufactures, and markets a range of contact lenses, including spherical lenses, and toric and multifocal lenses that correct near- and farsightedness, as well as addresses various complex visual defects, such as astigmatism and presbyopia.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Cooper Companies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cooper Companies and related companies with MarketBeat.com's FREE daily email newsletter.